GNRHR and ovarian cancer: In a mouse ovarian cancer model, local administration of the gonadotropin-releasing hormone receptor (GNRHR)-targeted peptide EP-100 was combined with anti-PD-L1-generating NK cell, DC and CD8 T cell tumour infiltration.